Sensipar — CareFirst (Caremark)
Persistent hyperparathyroidism in post-kidney transplant patients
Initial criteria
- Member has had a kidney transplant
- Serum calcium level (corrected for albumin) ≥ 8.4 mg/dL
Reauthorization criteria
- Member is experiencing benefit from therapy (e.g., decreased or normalized corrected serum calcium levels since starting therapy)
Approval duration
12 months